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OBJECTIVE—Transforming growth factor- (TGF-) can ex-
hibit strong immune suppression but has also been shown to
promote T-cell growth. We investigated the differential effect of
this cytokine on CD8
 T-cells in autoimmunity and antiviral
immunity.
RESEARCH DESIGN AND METHODS—We used mouse mod-
els for virally induced type 1 diabetes in conjunction with
transgenic systems enabling manipulation of TGF- expression
or signaling in vivo.
RESULTS—Surprisingly, when expressed selectively in the pan-
creas, TGF- reduced apoptosis of differentiated autoreactive
CD8
 T-cells, favoring their expansion and inﬁltration of the
islets. These results pointed to drastically opposite roles of
TGF- on naı ¨ve compared with antigen-experienced/memory
CD8
 T-cells. Indeed, in the absence of functional TGF- signal-
ing in T-cells, fast-onset type 1 diabetes caused by activation of
naı ¨ve CD8
 T-cells occurred faster, whereas slow-onset disease
depending on accumulation and activation of antigen-experi-
enced/memory CD8
 T-cells was decreased. TGF- receptor–
deﬁcient CD8
 T-cells showed enhanced activation and
expansion after lymphocytic choriomeningitis virus infection in
vivo but were more prone to apoptosis once antigen experi-
enced and failed to survive as functional memory cells. In
vitro, TGF- suppressed naı ¨ve CD8
 T-cell activation and
-interferon production, whereas memory CD8
 T-cells stim-
ulated in the presence of TGF- showed enhanced survival
and increased production of interleukin-17 in conjunction with
-interferon.
CONCLUSIONS—The effect of TGF- on CD8
 T-cells is de-
pendent on their differentiation status and activation history.
These results highlight a novel aspect of the pleiotropic nature of
TGF- and have implications for the design of immune therapies
involving this cytokine. Diabetes 57:2684–2692, 2008
T
ransforming growth factor 1 (TGF-)i sam u l -
tifunctional cytokine that acts on a wide assort-
ment of cell types regulating both cell growth
and differentiation. TGF- can have potent inhib-
itory effects on T-cell proliferation, cytokine production,
and cytolytic functions (1). In addition, the development of
mice lacking functional TGF- receptor signaling speciﬁ-
cally in T-cells has illustrated the important role of TGF-
in maintaining normal immune homeostasis (2,3). How-
ever, despite the clear inhibitory effects of TGF- on
T-cells, several studies also demonstrate that this cytokine
can in certain circumstances enhance the growth of T-cells
(4–6). For example, TGF-, along with interleukin (IL)-2,
enables prolonged CD4
 T-cell effector expansion (4). The
enhanced accumulation of T-cells cultured in TGF- may
be at least in part caused by the antiapoptotic effect of this
cytokine (4,5,7).
The diverse effects of TGF- are dependent on T-cell
type (Th1, Th2, CD4
, CD8
), differentiation status (naı ¨ve
versus memory), and microenvironment (cytokine and
cellular milieu) (4,6,8). Because of its ability to inhibit
T-cell responses, many studies have evaluated TGF- as a
potential therapeutic agent for treating autoimmune dis-
eases like type 1 diabetes. Indeed, systemic administration
of TGF- was shown to protect from this disease (9). In
addition, TGF- is produced on therapy or induction of
regulatory T-cells that protect from type 1 diabetes (10,11).
Transgenic expression of TGF- in pancreatic -cells was
also found to prevent diabetes in the NOD model for type
1 diabetes (12–14). However, in other diabetes models,
TGF- expressed in the islets either had no effect (15) or
resulted in spontaneous disease when expressed along
with tumor necrosis factor- (16). A superimposed prob-
lem in some of these previous studies was that constitutive
expression of TGF- led to signiﬁcant ﬁbrosis in the islets,
which made interpretation of the ﬁndings more difﬁcult
(15). Overall, little is known about the effect of TGF- on
CD8
 T-cells in type 1 diabetes.
Here, we examined the role of TGF- on CD8
 T-cell
effector functions in the pathogenesis of virally induced
type 1 diabetes by using transgenic mouse models allow-
ing for precise tracking of the autoreactive CD8
 T-cell
response, selective expression of TGF- in the pancreatic
islets, or elimination of functional TGF- receptor expres-
sion on T-cells. The RIP-LCMV mouse model for virally
induced type 1 diabetes (17,18) is well suited to address
the role played by TGF- in autoimmunity while at the
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immunity. RIP-LCMV mice express viral antigens from
LCMV under the control of RIP selectively on pancreatic
-cells and, in some lines, in the thymus (19). In C57BL/6
RIP-LCMV–glycoprotein (RIP-GP) and BALB/c RIP-
LCMV–nucleoprotein (RIP-NP) mice, which do not ex-
press the viral antigen in the thymus, infection with LCMV
induces rapid CD8
 T-cell–dependent diabetes. In con-
trast, disease develops more slowly in C57BL/6 RIP-NP
mice as a consequence of expression of the LCMV nucleo-
protein not only in the pancreas but also the thymus. In
C57BL/6 RIP-NP mice, LCMV infection is cleared before
insulitis and autoimmunity fully develop. In this model, the
CD8
 T-cells inﬁltrating the islets are of the memory
effector phenotype, whereas in the more rapid diabetes
models, primary activation of naı ¨ve CD8
 T-cells in lym-
phoid organs in the periphery on viral infection is respon-
sible for -cell destruction.
In the current study, we crossed RIP-LCMV mice to
different mouse trains which enabled control over TGF-
expression or signaling. First, we used the tetracycline-
dependent TGF- gene transcription system (TTA/TGF-)
(14), thereby allowing for TGF- expression selectively in
the islets to be turned on and off at will. This strategy
appeared necessary in light of earlier studies showing that
constitutive expression of TGF- in islets leads to pro-
found ﬁbrosis, making immunologic interpretation difﬁcult
(12,13). Second, we used dnTGFR transgenic mice whose
T-cells lack expression of the receptor for TGF- as a
result of transgenic expression of a dominant-negative
form of TGF- receptor selectively in T-cells (2). The
double-transgenic mice generated using the RIP-LCMV and
TTA/TGF- or dnTGFR strains constituted ideal models
to address the role of TGF- in autoreactive and antiviral
CD8
 T-cell responses in vivo. Our results highlight a
differential effect of TGF- on naı ¨ve compared with anti-
gen-experienced/memory CD8
 T-cells and their function
in virally induced type 1 diabetes.
RESEARCH DESIGN AND METHODS
TTA/TGF- mice expressing TGF- selectively on -cells on removal of
doxycycline from the diet were generated on the NOD background (14) and
crossed with BALB/c mice. TTA/TGF- mice on the BALB/c background were
crossed with BALB/c RIP-NP mice. dnTGFR mice on the C57BL/6 back-
ground (2) were crossed onto the C57BL/6 RIP-GP and C57BL/6 RIP-NP lines
(18,19). Naı ¨ve T-cell receptor transgenic P14 mice on the C57BL/6 background
(20) were used to obtain GP33-speciﬁc CD8
 T-cells. All mice were 6–9 weeks
old when used in experiments. In all experiments using transgenic RIP-LCMV
mice for diabetes studies, transgene-positive and -negative RIP-LCMV litter-
mates were used. Blood glucose was monitored using the OneTouch Ultra
system (LifeScan) at weekly intervals. Diabetes was deﬁned as blood glucose
values 300 mg/dl (21).
Virus and peptides. LCMV Armstrong clone 53b (22) was used throughout all
experiments. Virus was plaque-puriﬁed three times on Vero cells, and stocks
were prepared by a single passage on BHK-21 cells. Mice were infected with
a single dose of 10
5 plaque-forming units intraperitoneally. The dominant
H2-l
d–restricted LCMV epitope NP118–126 (NP118) or the dominant H2-D
b–
restricted LCMV epitope GP33–41 (GP33) (LIAI Peptide Core Facility) were
used for viral and diabetes studies (23).
Immunohistochemistry. For all stainings, 6- to 10-m tissue sections were
cut using a cryomicrotome and sialin-coated Superfrost Plus slides (Fisher
Scientiﬁc). For TGF- staining, tissues were ﬁxed in 4% formalin and parafﬁn
embedded. Sections were then rehydrated, quenched with H2O2 to block
endogenous peroxidase, and treated in a microwave oven in the presence of
citrate buffer (10 mmol/l, pH 6.0) for 10 min (two cycles of 5 min each). TGF-
was stained using rabbit anti-mouse TGF-1 (Santa Cruz Biotechnology) and
biotinylated anti-rabbit secondary antibody (Vector Laboratories). For CD8
staining, tissues were immersed in Tissue-Tek O.C.T. (Bayer) and snap-frozen
on dry ice. Sections were then ﬁxed with 90% ethanol at 20°C and washed
with PBS, and avidin/biotin was blocked using a commercial kit (Vector
Laboratories). CD8 was stained using rat anti-mouse CD8 (BD Biosciences)
and biotinylated anti-rat secondary antibody (Vector Laboratories) for 60 min
each. For both TGF- and CD8 staining, the color reaction was performed by
sequential incubation with avidin-peroxidase conjugate (Vector Laboratories)
and diaminobenzidine-hydrogen peroxide. Terminal deoxynucleotidyl trans-
ferase biotin-dUTP nick-end labeling (TUNEL) was performed using an
ApopTag kit (Intergen Company).
Isolation of lymphocytes from the pancreas. Pancreata were collected and
pancreatic draining lymph nodes removed. Pancreata were mechanically
disrupted using glass slides. Material was pooled from three to four mice, and
lymphocytes were isolated using a lympholyte sucrose gradient (CedarLane).
Flow cytometry. Fluorescently labeled monoclonal antibodies were obtained
from BD Biosciences, eBioscience, BioLegend, or Caltag. H2-l
d/NP118 or
H2-D
b/GP33 tetramers were produced as previously described (24). Cells were
processed on a LSRII or FACScalibur (BD Biosciences) and results analyzed
using FlowJo (Tree Star). For intracellular staining, single-cell suspensions
were stimulated as described, stained for surface molecules, ﬁxed in 2%
paraformaldehyde (Sigma-Aldrich), permeabilized, and stained for intracellu-
lar cytokines in buffer containing 0.05% saponin (Sigma-Aldrich). Annexin V
staining was performed using a commercial kit (BD Biosciences).
Cell culture. For dendritic cell puriﬁcation, spleens and mesenteric lymph
nodes were pooled from naı ¨ve C57BL/6 mice and disrupted using collagenase
D (Roche) in Hanks’ balanced salt solution media (Invitrogen). Dendritic cells
were then puriﬁed by magnetic separation using anti-CD11c MACS mi-
crobeads, washed, and loaded for2ha t37°C with 3 g/ml GP33 peptide.
Alternatively, cells were infected with LCMV at multiplicity of infection (MOI)
of 0.1 on start of culture. Naı ¨ve or memory CD8
 T-cells were puriﬁed by
magnetic separation using anti-CD8 MACS microbeads. T-cells were labeled
for 10 min with 5 mol/l 5(6)-carboxyﬂuorescein diacetate N-succinimidyl
ester (CFSE; Sigma-Aldrich), washed, and cultured with GP33-loaded den-
dritic cells (at a ratio of 1 dendritic cell to 3 T-cells) in RPMI 1640 (Invitrogen)
supplemented with 10% FCS (Hyclone), 2 mmol/l L-glutamine (Sigma-Aldrich),
and 50 mol/l 2-mercaptoethanol (Sigma-Aldrich), in the presence or absence
of 3 ng/ml recombinant human TGF-1 (R&D systems). Then, 3 days later,
Brefeldin A was added to the wells for 4 h, and cells were stained for
intracellular cytokines.
RNase protection assay. Total RNA was isolated from CD8
 T-cells with
chloroform using TRI reagent (Molecular Research Center), precipitated with
isopropanol, and washed with ethanol. We used 5 g of total RNA for
hybridization with a
32P-UTP–labeled multitemplate obtained from a commer-
cial kit (RiboQuant, mCYC-1; BD Biosciences). RNase protection assay was
carried out according to the manufacturer’s guidelines. The resulting analyt-
ical acrylamide gel was scanned using a Storm 860 PhosphorImaging system
(Molecular Dynamics), and the intensity of bands corresponding to protected
mRNAs was quantiﬁed with ImageQuant image analysis software (Molecular
Dynamics) using L32 as a reference gene.
Statistical analysis. Data are expressed as the means  SD. Statistical
signiﬁcance was determined using Student’s t test, and differences were
considered signiﬁcant when P 	 0.05.
RESULTS
Mice induced to express TGF- in the islets show
increased islet inﬁltration by autoreactive CD8
 T-
cells activated in the periphery. We investigated the
effect of TGF- expression locally in the pancreas of
RIP-LCMV mice. BALB/c RIP-NP mice were generated in
the tetracycline-dependent TGF- gene transcription sys-
tem (TTA/TGF-), which allows for TGF- expression
in the islets to be turned on and off at will. TGF- transcrip-
tion was induced by removing doxycycline from the diet of
double-transgenic TTA/TGF-
BALB/c RIP-NP mice
(RIP-NP.TGF mice). Then, 1 week later, these mice were
infected with LCMV and analyzed 7 days later for TGF-
expression in the islets by immunohistochemistry. Only
RIP-NP.TGF mice that were fed a doxycycline-free diet
expressed the TGF- protein selectively in the islets,
whereas doxycycline-fed RIP-NP.TGF mice and their
transgene-negative littermates did not (Fig. 1A). The islets
of naı ¨ve RIP-NP.TGF mice fed a doxycycline-free diet
showed no sign of inﬁltration (data not shown). On the
other hand and surprisingly, TGF- expression in the
pancreas of LCMV-infected RIP-NP mice induced the
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 T-cells with diabetogenic proper-
ties (15), reﬂecting their previous activation in the periph-
ery (17,18). These observations indicate an enhancing
effect of TGF- on the survival of previously activated
CD8
 T-cells. Furthermore, whereas RIP-NP mice and
RIP-NP.TGF mice fed doxycycline displayed comparable
inﬁltration, with CD8
 T-cells present mostly around the
periphery of the islets, the islets of RIP-NP.TGF- mice
induced to express TGF- by removal of doxycycline were
massively inﬁltrated with CD8
 T-cells. In addition, tet-
ramer staining of lymphocytes from pooled pancreata of
mice fed a doxycycline-free diet revealed the presence of
twice as many nucleoprotein-speciﬁc CD8
 T-cells in the
pancreas of TGF-–expressing compared with control
RIP-NP mice (Fig. 1B). Of note, accumulation of CD8
 T
effectors was seen only in the pancreas, where TGF- was
expressed, but not in the spleen and pancreatic draining
lymph node. Accordingly, systemic immunity to LCMV was
identical in TGF-–expressing and control mice, which
cleared the infection with similar kinetics (data not shown).
TGF- promotes the survival of previously activated
autoreactive CD8
 T-cells by decreasing their apo-
ptosis. To identify the cause for the increased number of
autoreactive effectors in TGF-–expressing islets, we as-
sessed apoptosis of these cells by TUNEL. At 7 days after
infection with LCMV, the number of TUNEL-positive cells
appeared smaller in inﬁltrated islets of RIP-NP.TGF mice
than in those of their RIP-NP littermates (Fig. 2A), which
indicated that TGF- reduced apoptosis of previously
activated CD8
 T-cell effectors. However, it was difﬁcult to
compare apoptosis quantitatively in the islets of RIP-
NP.TGF and RIP-NP mice, which differed in the extent of
inﬁltration. Cell suspensions were thus prepared from
pooled pancreata 7 days after infection and stained with
H2-l
d/NP118 tetramers and annexin V. As shown in Fig. 2A,
the frequency of nucleoprotein-speciﬁc CD8
 T-cells ex-
pressing annexin V was higher in RIP-NP.TGF mice
induced to express TGF- in the islets by doxycycline
removal compared with control RIP-NP littermates. There-
fore, expression of TGF- in the vicinity of previously
activated CD8
 T-cells led to their enhanced survival and
subsequent accumulation at the effector site. These results
indicate that CD8
 T-cell effectors that have previously
responded to antigenic stimulation are enhanced rather
than suppressed by TGF-. Accordingly, TGF- did not
hinder but rather enhanced the capacity of antigen-expe-
rienced CD8
 T-cells obtained from LCMV-immune
BALB/c mice to proliferate in response to LCMV in vitro
and did not prevent upregulation of the cell cycle proteins
cyclin D and A2 (Fig. 2B) (25). In fact, binding of annexin
V to these cells was signiﬁcantly reduced in the presence
of TGF-, indicating an antiapoptotic effect of this cyto-
kine on antigen-experienced CD8
 T-cells (Fig. 2C).
Absence of TGF- receptor signaling in T-cells has
opposing effects on autoimmune diabetes depending
on the effector mechanism. These observations pointed
to opposite roles of TGF- on naı ¨ve compared with
antigen-experienced/memory CD8
 T-cells. We thus eval-
uated the impact of TGF- in two type 1 diabetes models
that differed in terms of requirement for CD8
 T-cell
activation: the fast-onset C57BL/6 RIP-GP model, which is
caused by robust activation of naı ¨ve CD8
 T-cells, and the
slow-onset C57BL/6 RIP-NP model, which results from
accumulation and activation of antigen-experienced/mem-
ory CD8
 T-cells. We generated C57BL/6 RIP-GP and
C57BL/6 RIP-NP mice in which autoreactive CD8
 T-cells
are unable to signal through the TGF- receptor by cross-
ing these mice with dnTGFR mice, which express a
dominant-negative TGF- receptor speciﬁcally in T-cells.
Although “naı ¨ve-dependent” fast-onset diabetes was dra-
matically accelerated in RIP-GP.dnTGFR compared with
RIP-GP mice (Fig. 3A), incidence of “memory-dependent”
slow-onset diabetes was reduced more than twofold in
RIP-NP.dnTGFR compared with RIP-NP mice (Fig. 3B).
Absence of TGF- receptor signaling in T-cells resulted in
a threefold increase in the total number of LCMV-speciﬁc
CD8
 T-cells in the spleen 7 days after LCMV infection
(Fig. 4A). Thus, impaired responsiveness of naı ¨ve CD8

T-cells to TGF- enhanced their activation and expansion,
which likely accounted for accelerated diabetes in the
RIP-GP.dnTGFR group and in the few RIP-NP.dnTGFR
mice that developed disease (between 1 and 2 weeks after
infection in this otherwise slow-onset model). However,
by day 30 the overall number of GP33-speciﬁc CD8

T-cells was similar in wild-type and dnTGFR mice (Fig.
4B), indicating that TGF-–nonresponsive CD8
 T-cells
had undergone increased contraction. Furthermore,
TGF- receptor–deﬁcient memory CD8
 T-cells were
more prone to apoptosis (Fig. 4C) and completely defec-
tive in terms of secondary expansion (Fig. 4D) when
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FIG. 1. Mice induced to express TGF- in the islets show increased islet
inﬁltration by autoreactive CD8
 T-cells activated in the periphery.
TTA/TGF- BALB/c mice were crossed with BALB/c RIP-NP mice to
generate double-transgenic RIP-NP.TGF offspring. RIP-NP.TGF
mice and their single-transgenic RIP-NP littermates were fed a diet
containing doxycycline (dox) during gestation and after birth. A:
Doxycycline was either maintained or removed from the diet 7 days
before infection with LCMV, and pancreata were harvested 7 days later
(day 14 after doxycycline removal). Tissue sections were analyzed for
TGF- production and CD8
 T-cell inﬁltration after staining with
anti–TGF- (top panels) or anti-CD8 (bottom panels) and counter-
staining with hematoxylin. B: Single-cell suspensions were prepared
from the pancreas, spleen, or pancreatic draining lymph nodes (PDLN)
of mice fed a doxycycline-free diet. The frequency of NP118-speciﬁc/
responsive CD8
 T-cells was evaluated in pooled pancreata (three to
four) by tetramer staining and in the spleen and pancreatic draining
lymph nodes by ﬂow cytometry after stimulation with NP118 ex vivo.
(Please see http://dx.doi.org/10.2337/db08-0609 for a high-quality digi-
tal representation of this ﬁgure.)
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vitro. Thus, impaired responsiveness of activated CD8

T-cells to TGF- diminished their survival and mainte-
nance as memory cells, which likely accounted for re-
duced slow-onset diabetes in the RIP-NP.dnTGFR
system. This indicates that TGF- prevents activation of
naı ¨ve CD8
 T-cells, which cause fast-onset diabetes, but
promotes the survival and accumulation of antigen-expe-
rienced cells, which cause slow-onset disease.
TGF- suppresses naı ¨ve CD8
 T-cell activation and
enhances the survival and effector function of anti-
gen-experienced/memory CD8
 T-cells. Based on
these observations, we investigated in further detail the
differential effect of TGF- on activation, proliferation, and
effector function of naı ¨ve compared with antigen-experi-
enced/memory CD8
 T-cells. This was addressed by com-
paring the response mounted in vitro by naı ¨ve and memory
GP33-speciﬁc CD8
 T-cells stimulated with GP33-loaded
dendritic cells in the presence or absence of TGF-.W e
observed that naı ¨ve CD8
 T-cells lost their capacity to
produce -interferon (IFN-) when stimulated in the pres-
ence of TGF- (Fig. 5A and B). Interestingly, IL-17 produc-
tion by these cells was, on the other hand, increased,
though modestly, indicating that TGF- favored a switch
of CD8
 T-cells from a Th1-like (Tc1) to a Th17-like
phenotype (Tc17). Furthermore, naı ¨ve CD8
 T-cells stim-
ulated in the presence of TGF- showed impaired prolif-
eration associated with upregulation of cyclin D but not A2
(Fig. 5C and D), which indicated a block in the S phase of
the cell cycle (26). In addition, binding of annexin V and
expression of the proapoptotic molecule programmed
death 1 (PD-1) (27) on stimulated naı ¨ve cells was in-
creased by TGF- (Fig. 5E). In marked contrast, TGF- did
not affect proliferation of stimulated GP33-speciﬁc mem-
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FIG. 2. TGF- promotes the survival of previously activated autoreactive CD8
 T-cells by decreasing their apoptosis. A: Apoptosis was evaluated
by TUNEL in pancreatic tissue sections obtained from mice fed a doxycycline (dox)-free diet (top panels). Cell suspensions were prepared from
the pooled pancreatic draining lymph nodes of three to four mice and stained with H2-l
d/NP118 tetramers and annexin V (bottom panels).
Histograms show the frequency of tetramer-positive CD8
 T-cells stained with annexin V. B: CD8
 T-cells were puriﬁed from the spleen of
LCMV-immune BALB/c mice, labeled with CFSE, and cultured with LCMV-infected, irradiated, antigen-presenting cells in the presence or absence
of 3 ng/ml rhTGF-1. Cell proliferation was assessed by measuring CFSE dilution by ﬂow cytometry after 6 days in culture (top panel) or cell cycle
protein RNA was quantitated by RNase protection assay after 24 h (bottom panel). C: CD8
 T-cells were isolated from the spleen of
LCMV-immune BALB/c mice and cultured with LCMV-infected, irradiated, antigen-presenting cells in the presence or absence of 3 ng/ml
rhTGF-1. After 1 and 3 days in culture, T-cells were analyzed for apoptosis by ﬂow cytometry after staining with annexin V. Data represents the
average frequency of CD8
 T-cells stained with annexin V  SD from three independent experiments. (Please see http://dx.doi.org/10.2337/db08-
0609 for a high-quality digital representation of this ﬁgure.)
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 T-cells, consistent with our observation in Fig.
2C using polyclonal memory CD8
 T-cells (Fig. 5C).
Furthermore, although IL-17 production was increased in
GP33-speciﬁc memory cells (as observed in naı ¨ve GP33-
speciﬁc cells), the overall increase was greater in these
compared with naı ¨ve cells and not accompanied by a loss
in IFN- production (Fig. 5A and B). In addition, as
opposed to naı ¨ve cells, memory cells stimulated in the
presence of TGF- showed decreased apoptosis and did
not upregulate PD-1 (Fig. 5E). These observations indicate
that TGF- not only increases the survival of activated
antigen-experienced/memory CD8
 T-cells but also en-
hances their capacity to produce IL-17 in the presence of
IFN- by inducing an incomplete switch from Tc1 to Tc17.
DISCUSSION
We observed that TGF- expression in the vicinity of
already activated autoreactive T-cells promotes their sur-
vival and accumulation, which highlighted a differential
effect of TGF- on CD8
 T-cell responses derived from
naı ¨ve versus antigen-experienced/memory progenitors.
Our results show that the role of TGF- in type 1 diabetes
is highly dependent on the differentiation state and activa-
tion history of CD8
 T-cells. We found that TGF- inhibits
activation and proliferation of naı ¨ve but not antigen-
experienced/memory effector CD8
 T-cells. Furthermore,
TGF- exerts an antiapoptotic effect on activated antigen-
experienced CD8
 T-cells and thus enhances their sur-
vival. In addition, TGF- promotes a switch from a Tc1 to
a Tc17 phenotype, which is incomplete in stimulated
memory cells, resulting in both IFN- and IL-17 production
by these cells. These results correlate precisely with our
observation that lack of a functional TGF- receptor on
T-cells has enhancing and dampening effects on diabetes
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FIG. 3. Absence of TGF- receptor signaling in T-cells has opposite
effects on virally induced autoimmune diabetes depending on the
effector mechanism. dnTGFR mice were crossed onto fast-onset
diabetes RIP-GP or slow-onset diabetes RIP-NP lines. Groups of RIP-
GP.dnTGFR( A) mice, RIP-NP.dnTGFR( B) mice, and their single
transgenic RIP-GP or RIP-NP littermates were infected with LCMV, and
diabetes incidence was monitored by measuring blood glucose. Mice
were considered diabetic when blood glucose exceeded 300 mg/dl.
FIG. 4. Absence of TGF- receptor signaling in T-cells enhances
antiviral CD8
 T-cell responses at the acute phase but reduces memory
responses. dnTGFR mice and their wild-type (WT) C57BL/6 litter-
mates were infected with LCMV. A and B: Mice were killed and spleens
harvested on day 7 (peak) (A) or 28 (memory) (B) postinfection. The
frequency of IFN-–producing cells (measured by ﬂow cytometry after
stimulation with GP33) was multiplied by the total number of spleno-
cytes to obtain the number of GP33-responsive CD8
 T-cells per
spleen. Data represents the average number of GP33-responsive CD8

T-cells per spleen  SD from three individual mice per group. f,
wild-type; , dnTGFR. C: Splenocytes were harvested from dnTGFR
mice 28 days postinfection, labeled with CFSE, and cultured with
LCMV-infected, irradiated, antigen-presenting cells. Cells were har-
vested 2 or 3 days later and stained for expression of CD8 and annexin
V. Data represents the average frequency of CD8
 T-cells stained with
annexin V  SD from three mice per group. D: Alternatively, cells were
harvested 6 days later and analyzed for IFN- production by ﬂow
cytometry after stimulation with GP33. Representative ﬂuorescence-
activated cell sorting plots are shown.
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memory CD8
 T-cells, respectively. Previous work also
indicates divergent effects of TGF- on naı ¨ve versus
differentiated CD4
 T-cells in vitro (28,29).
Our results using TTA/TGF-
BALB/c RIP-NP mice
(RIP-NP.TGF) stand in some contrast to studies in the
NOD mouse, in which constitutive expression of TGF- in
the islets prevented diabetes (12,13,30). Similarly, in stud-
ies using TTA/TGF- NOD mice, where no ﬁbrosis was
observed, TGF- exerted a protective effect on type 1
diabetes (14). An important factor might thus be whether
priming of autoreactive T-cells occurs in the periphery or
within the islets of Langerhans. Based on our present
observations, one would expect TGF- to have a protec-
tive effect at locations where priming of naı ¨ve CD8

T-cells occurs. In NOD mice, it is possible that a signiﬁcant
proportion of priming occurs locally in the islets of Lang-
erhans or in the pancreatic draining lymph nodes, where
the earliest signs of immunopathogenesis are seen. Previ-
ous observations in NOD mice show that priming in the
islets and the lymph nodes are not necessarily linked (31).
In contrast, in RIP-LCMV models for fast-onset diabetes
(BALB/c RIP-NP and C57BL/6 RIP-GP), activation of auto-
reactive T-cells occurs in the periphery in lymphoid organs
and at sites of viral replication. Furthermore, in these
models, as opposed to the slow-onset C57BL/6 RIP-NP
model, maintenance of antigen-experienced/memory cells
over time is not necessary for attack and destruction of
-cells. Thus, the antiapoptotic effect of TGF- on effector
T-cells will outweigh its suppressive function on naı ¨ve
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FIG. 5. TGF- suppresses naı ¨ve CD8
 T-cell activation and enhances the survival and effector function of antigen-experienced/memory CD8

T-cells. CD8
 T-cells were puriﬁed from the spleen of naı ¨ve P14 or LCMV-immune C57BL/6 mice, labeled with CFSE, cultured with GP33-loaded
dendritic cells in the presence or absence of 3 ng/ml rhTGF-1, and harvested 2 days later. A and B: Cells were analyzed for IFN- and IL-17
production by ﬂow cytometry after stimulation with GP33. Data represents the average frequency of naı ¨ve (A) and memory (B) CD8
 T-cells
producing IFN- or IL-17  SD from three individual mice per group. C: Cell proliferation was assessed by measuring CFSE dilution by ﬂow
cytometry. Representative ﬂuorescence-activated cell sorting plots are shown. Values show the percentage of naı ¨ve (left panel) or memory (right
panel) CD8
 T-cells that have undergone at least one division on stimulation in the presence or absence of TGF-SD from three individual
mice per group. D: Naı ¨ve GP33-speciﬁc CD8
 T-cells were analyzed for cell cycle protein RNA by RNase protection assay as described in Fig. 2B.
E: Cells were analyzed by ﬂow cytometry for apoptosis after staining with annexin V or for expression of PD-1. Data represents the average
frequency of CD8
 T-cells stained with annexin V (left panel) or expressing PD-1 (right panel)  SD from three individual mice per group.
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previous observation that TGF- does not protect against
already differentiated diabetogenic T-cells, as evidenced
by similar destruction of TGF-–expressing and control
islet transplants in diabetic mice (13,15). Thus, our results
suggest that TGF- will have different effects in vivo
depending on where priming of autoreactive T-cells
occurs.
We found that in the absence of TGF- receptor signal-
ing in T-cells, priming and expansion of naı ¨ve antiviral/
autoreactive CD8
 T-cells are enhanced in vivo. Although
this might be caused by a direct effect of TGF- on naı ¨ve
CD8
 T-cells, it is also possible that absence of TGF-
receptor signaling decreases the function or induction of
regulatory T-cells, which thereby enables enhanced naı ¨ve
T-cell activation. Previous work has shown that human
CD4
CD25
 regulatory T-cells can be expanded in vitro
using TGF- (32). In the mouse, TGF- was shown to
prevent spontaneous type 1 diabetes by promoting the
expansion of CD4
CD25
 regulatory T-cells in the islets
(14). Furthermore, it was recently shown that expression
of TGF- selectively in -cells promotes the induction of
CD4
CD25
 regulatory T-cells that protect from virally
induced type 1 diabetes (30). However, expansion of
regulatory T-cells in the mouse in vivo occurred only when
TGF- was expressed early, starting from birth (14), or
constitutively in the islets (30). Furthermore, as discussed
above, the effect of TGF- might rely on where T-cell
priming occurs in vivo. This further underscores our
observation that the effect of TGF- on T-cells depends on
their activation/differentiation state. Of note, the role of
TGF- in the function of CD4
CD25
 regulatory T-cells is
not clear, with some work demonstrating an important
role for this cytokine (10,33–35), and other no involvement
(36). In any case, we observed that naı ¨ve CD8
 T-cells
isolated from CD4
 T-cells and stimulated in vitro in the
presence of TGF- show impaired activation and prolifer-
ation, indicating that CD4
 regulatory T-cells are not
involved in the process. Furthermore, we observed no
upregulation of Foxp3 or decrease in CD127 expression on
naı ¨ve CD8
 T-cells stimulated in the presence of TGF-
(data not shown), making it unlikely that TGF- induced
the differentiation of CD8
 regulatory T-cells. Thus, im-
paired TGF- receptor signaling in T-cells enhanced acti-
vation of naı ¨ve T-cells and impaired the survival of
memory T-cells in vivo most likely as a direct effect of
TGF- on CD8
 T-cell effectors. As a consequence, fast-
onset diabetes, which depends on activation of naı ¨ve
T-cells, was accelerated, whereas slow-onset diabetes,
which requires maintenance of antigen-experienced/mem-
ory effectors, was reduced.
Our results indicate that the importance of TGF- for
the survival of antigen-experienced/memory T-cells and
their subsequent effect on type 1 diabetes is attributable at
least partially to the antiapoptotic properties of this cyto-
kine. We observed that TGF- receptor-deﬁcient CD8

T-cells are more prone to apoptosis and harbor impaired
capacity of secondary expansion. In this respect, previous
work by others indicates that T-cells derived from TGF-
–deﬁcient mice show enhanced apoptosis in vitro
(37,38). In vitro, we found that TGF- diminishes annexin
V binding and thus apoptosis of CD8
 T-cell effectors
derived from memory but not naı ¨ve precursors. Accord-
ingly, TGF- was reported to have potent antiapoptotic
effects in vitro, possibly as a result of inhibition of Fas
ligand and c-Myc expression (4,5,7). Although we did not
assess Fas ligand or c-Myc expression on T-cells stimu-
lated in vitro, we found that TGF- induced naı ¨ve but not
memory CD8
 T-cells to upregulate PD-1, which is a
proapoptotic molecule that controls T-cell responses in
both LCMV infection and type 1 diabetes (27,39–42). In
vivo, we found that expression of TGF- locally in the
islets results in accumulation of autoreactive CD8
 T-cell
effectors, which exhibited reduced apoptosis. Importantly,
the frequency of antigen-speciﬁc CD8
 T-cells was en-
hanced only in the vicinity of TGF- in the islets, but not
in the spleen or pancreatic draining lymph node. In other
words, absence of TGF- expression in the periphery
enabled naı ¨ve CD8
 T-cell activation to occur normally in
the spleen and pancreatic draining lymph node, whereas
TGF- expressed locally in the islets exerted its antiapop-
totic effect on subsequently activated effectors inﬁltrating
the pancreas.
Based on our observations, another important parame-
ter accounting for the differential effect of TGF- on naı ¨ve
compared with antigen-experienced/memory CD8
 T-cells
might be their capacity to produce IL-17. It was recently
reported that TGF- can induce IL-17 production by CD4

T-cells when acting in combination with the proinﬂamma-
tory cytokine IL-6 (43). Such Th17 cells produce IL-17 but
not IFN-, which actually inhibits their differentiation and
function (44,45). Th17 cells and IL-17 production might
play a crucial role in mediating pathology in autoimmune
diseases such as multiple sclerosis (43). In fact, IL-17 is an
important regulator of inﬂammation and is elevated in a
number of inﬂammatory conditions (46). IL-17 production
by CD8
 T-cells (Tc17) has also been described and shown
to harbor colitogenic properties (47). Although the role of
Th17/Tc17 cells and IL-17 in type 1 diabetes is not under-
stood, a recent report indicates that normoglycemia can
be restored but not prevented in NOD mice through
inhibition of IL-17 production after antigen administration
(48). Therefore, although IL-17 may not initiate -cell
destruction, it may contribute to pathology once autoim-
munity has been induced. We do not know whether IL-17
production plays a role in the pathological function of
memory CD8
 T-cells stimulated in the presence of
TGF-. However, we observed that these cells, as opposed
to naı ¨ve cells, are also capable of producing IFN- and
thus likely to cause -cell destruction. It is thus possible
that TGF- provides memory CD8
 T-cells with enhanced
capacity to exacerbate -cell destruction once they have
initiated it. On the other hand, naı ¨ve cells stimulated with
TGF-, despite their capacity to produce IL-17, are not
capable of IFN- production and might thus lack essential
properties to be pathological.
Our results also have important implications for under-
standing the factors required to optimize antiviral vac-
cines, where the objective is to generate and maintain an
optimal number of memory T-cells rather than inducing a
strong primary response to the vaccine. Based on our
observations, TGF-, which is normally thought of as an
immune dampening factor, might actually be beneﬁcial for
expanding and maintaining such antiviral memory T-cells.
On the other hand, blockade of TGF- might be beneﬁcial
in situations where boosting the priming of effector T-cells
is desired. For example, mice deﬁcient in TGF- receptor
signaling generate an increased tumor-speciﬁc CD8
 T-cell
response that leads to tumor eradication and long-term
survival (49). Although it is not known whether these mice
generate long-term memory, for example after tumor
rechallenge, they nonetheless show improved survival
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tion. In our studies, reduced secondary expansion of
memory CD8
 T-cells to LCMV was observed in the
absence of TGF- receptor signaling, but viral clearance
occurred normally, probably because of the massive ex-
pansion of effector CD8
 T-cells that occurred during the
primary response. Thus, blockade of TGF- may still
constitute a strong therapeutic strategy for generating
antitumor immunity, even if long-term memory generation
is impaired.
In conclusion, our studies have implications for the
therapeutic use of TGF-. In autoimmune diseases such as
type 1 diabetes, TGF- may not always be inhibitory and
may actually act to enhance the survival of autoreactive
T-cells, depending on their differentiation state. Therefore,
it is possible that TGF- therapy initiated during the early
stages of autoimmune disease is beneﬁcial by suppressing
activation of naı ¨ve autoreactive T-cells or inducing regu-
latory T-cells, whereas late initiation of treatment may be
detrimental because most autoreactive T-cells are already
fully differentiated at this point. On the other hand, block-
ade of TGF- to boost immune responses, for example
after tumor cell vaccination, may enhance the priming of
T-cells but could have negative implications for the gen-
eration of long-lived memory T-cells. Thus, for systemic
treatments involving the administration or blockade of
TGF-, one will have to consider the precise balance of
naı ¨ve and effector/memory T-cells within the targeted
population.
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